RARE Ultragenyx

$29.78

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Ultragenyx

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.

Website: https://www.ultragenyx.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1515673
Address
60 LEVERONI COURT, NOVATO, CA, US
Valuation
Market Cap
$3.35B
P/E Ratio
nan
PEG Ratio
-0.24
Price to Book
13.13
Performance
EPS
$-6.29
Dividend Yield
—
Profit Margin
-101.60%
ROE
-211.70%
Technicals
50D MA
$39.14
200D MA
$46.66
52W High
$60.37
52W Low
$29.59
Fundamentals
Shares Outstanding
94M
Target Price
$91.80
Beta
0.61

RARE EPS Estimates vs Actual

● Estimated
● Actual

RARE News & Sentiment

Aug 21, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of ...
Aug 21, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 21, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 17, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 13, 2025 • Benzinga NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aug 12, 2025 • GlobeNewswire NEUTRAL
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around ...
Sentiment Snapshot

Average Sentiment Score:

0.136
50 articles with scored sentiment

Overall Sentiment:

Neutral

RARE Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-1.75
  • Whisper: —
  • Surprise %: 0.0%
Feb 13, 2025
Dec 31, 2024 (Post market)
-0.12 Surprise
  • Reported EPS: $-1.39
  • Estimate: $-1.27
  • Whisper: —
  • Surprise %: -9.4%
Nov 05, 2024
Sep 30, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $-1.40
  • Estimate: $-1.45
  • Whisper: —
  • Surprise %: 3.5%
Aug 01, 2024
Jun 30, 2024 (Post market)
0.17 Surprise
  • Reported EPS: $-1.52
  • Estimate: $-1.69
  • Whisper: —
  • Surprise %: 10.1%
May 02, 2024
Mar 31, 2024 (Post market)
-0.3 Surprise
  • Reported EPS: $-2.03
  • Estimate: $-1.73
  • Whisper: —
  • Surprise %: -17.3%
Feb 15, 2024
Dec 31, 2023 (Post market)
0.1 Surprise
  • Reported EPS: $-1.52
  • Estimate: $-1.62
  • Whisper: —
  • Surprise %: 6.2%
Nov 02, 2023
Sep 30, 2023 (Post market)
-0.15 Surprise
  • Reported EPS: $-2.23
  • Estimate: $-2.08
  • Whisper: —
  • Surprise %: -7.2%
Aug 03, 2023
Jun 30, 2023 (Post market)
-0.18 Surprise
  • Reported EPS: $-2.25
  • Estimate: $-2.07
  • Whisper: —
  • Surprise %: -8.7%
May 04, 2023
Mar 31, 2023 (Post market)
-0.35 Surprise
  • Reported EPS: $-2.33
  • Estimate: $-1.98
  • Whisper: —
  • Surprise %: -17.7%

Financials